Skip to main content Back to Top
Advertisement

5/27/2020

Clindamycin Phosphate Injection

Products Affected - Description

    • Cleocin injection, Pfizer, 150 mg/mL, 2 mL ADD-Vantage vial, 25 count, NDC 00009-6582-01
    • Cleocin injection, Pfizer, 150 mg/mL, 2 mL vial, 25 count, NDC 00009-0870-26
    • Cleocin injection, Pfizer, 150 mg/mL, 4 mL ADD-Vantage vial, 25 count, NDC 00009-3124-03
    • Cleocin injection, Pfizer, 150 mg/mL, 6 mL ADD-Vantage vial, 25 count, NDC 00009-3447-03
    • Clindamycin phosphate injection, Akorn, 300 mg/50 mL, in 5% dextrose premixed bottle, 1 count, NDC 17478-0120-50 - discontinued
    • Clindamycin phosphate injection, Akorn, 600 mg/50 mL, premixed bottle, 1 count, NDC 17478-0121-50 - discontinued
    • Clindamycin phosphate injection, Akorn, 900 mg/50 mL, premixed bottle, 1 count, NDC 17478-0122-50 - discontinued
    • Clindamycin phosphate injection, Almaject, 150 mg/mL, 2 mL ADD-Vantage vial, 25 count, NDC 72611-0762-25 - discontinued
    • Clindamycin phosphate injection, Almaject, 150 mg/mL, 4 mL ADD-Vantage vial, 25 count, NDC 72611-0767-25 - discontinued
    • Clindamycin phosphate injection, Almaject, 150 mg/mL, 6 mL ADD-Vantage vial, 25 count, NDC 72611-0769-25 - discontinued
    • Clindamycin phosphate injection, Baxter, 300 mg/50 mL, in 0.9% sodium chloride premixed container, 24 count, NDC 00338-9545-24
    • Clindamycin phosphate injection, Baxter, 300 mg/50 mL, in 5% dextrose premixed container, 24 count, NDC 00338-3410-24
    • Clindamycin phosphate injection, Baxter, 600 mg/50 mL, in 0.9% sodium chloride premixed container, 24 count, NDC 00338-9549-24
    • Clindamycin phosphate injection, Baxter, 600 mg/50 mL, in 5% dextrose premixed container, 24 count, NDC 00338-3612-24
    • Clindamycin phosphate injection, Baxter, 900 mg/50 mL, in 0.9% sodium chloride premixed container, 24 count, NDC 00338-9553-24
    • Clindamycin phosphate injection, Baxter, 900 mg/50 mL, in 5% dextrose premixed container, 24 count, NDC 00338-3814-24
    • Clindamycin phosphate injection, Sagent, 150 mg/mL, 2 mL vial, 25 count, NDC 25021-0115-02
    • Clindamycin phosphate injection, Sagent, 150 mg/mL, 4 mL vial, 25 count, NDC 25021-0115-04
    • Clindamycin phosphate injection, Sagent, 150 mg/mL, 6 mL vial, 25 count, NDC 25021-0115-06

Reason for the Shortage

    • Alvogen injectable generic products including clindamycin are being marketed under the brand, Almaject Inc., as of October 1, 2019. The NDC numbers for these products have changed.
    • Akorn discontinued clindamycin injection in early 2020.
    • Baxter has clindamycin injection on shortage due to manufacturing delays.
    • Fresenius Kabi did not provide a reason for the shortage.
    • Pfizer did not provide a reason for the shortages. Pfizer discontinued Cleocin premixed bags in 2018.
    • Sagent did not provide a reason for the shortage.
    • Sandoz did not provide a reason for the shortage.

Available Products

    • Cleocin injection, Pfizer, 150 mg/mL, 4 mL vial, 25 count, NDC 00009-0775-26
    • Cleocin injection, Pfizer, 150 mg/mL, 6 mL vial, 25 count, NDC 00009-0902-18
    • Cleocin injection, Pfizer, 150 mg/mL, 60 mL bulk vial, 5 count, NDC 00009-0728-09
    • Clindamycin phosphate injection, Almaject, 150 mg/mL, 2 mL vial, 25 count, NDC 72611-0634-25
    • Clindamycin phosphate injection, Almaject, 150 mg/mL, 4 mL vial, 25 count, NDC 72611-0639-25
    • Clindamycin phosphate injection, Almaject, 150 mg/mL, 6 mL vial, 25 count, NDC 72611-0642-25
    • Clindamycin phosphate injection, Almaject, 150 mg/mL, 60 mL bulk vial, 1 count, NDC 72611-0645-55
    • Clindamycin phosphate injection, Fresenius Kabi, 150 mg/mL, 2 mL vial, 25 count, NDC 63323-0282-02
    • Clindamycin phosphate injection, Fresenius Kabi, 150 mg/mL, 4 mL vial, 25 count, NDC 63323-0282-04
    • Clindamycin phosphate injection, Fresenius Kabi, 150 mg/mL, 6 mL vial, 25 count, NDC 63323-0282-06
    • Clindamycin phosphate injection, Fresenius Kabi, 150 mg/mL, 60 mL vial, 1 count, NDC 63323-0282-60
    • Clindamycin phosphate injection, Sagent, 150 mg/mL, 60 mL bulk vial, 1 count, NDC 25021-0115-51
    • Clindamycin phosphate injection, Sandoz, 300 mg/50 mL, in 5% dextrose premixed container, 24 count, NDC 00781-3288-09
    • Clindamycin phosphate injection, Sandoz, 600 mg/50 mL, in 5% dextrose premixed container, 24 count, NDC 00781-3289-09
    • Clindamycin phosphate injection, Sandoz, 900 mg/50 mL, in 5% dextrose premixed container, 24 count, NDC 00781-3290-09

Estimated Resupply Dates

    • Baxter has all clindamycin phosphate injection presentations on intermittent back order and the company is releasing product as it becomes available.
    • Pfizer has Cleocin 150 mg/mL 2 mL, 4 mL, and 6 mL ADD-Vantage vials on back order and the company estimates a release date of February 2023. The 150 mg/mL 2 mL vials are on back order and the company estimates a release date of June 2020.
    • Sagent has clindamycin phosphate 150 mg/mL 2 mL and 4 mL vials on back order and the company estimates a release date of June 2020. The 6 mL vials are on allocation.

Updated

Updated May 27, 2020 by Michelle Wheeler, PharmD, Drug Information Specialist. Created June 13, 2013 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2020, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.